WO2005026337A3 - Vecteur adenoviral pour l’infection de cellules deficientes en recepteur car - Google Patents

Vecteur adenoviral pour l’infection de cellules deficientes en recepteur car Download PDF

Info

Publication number
WO2005026337A3
WO2005026337A3 PCT/FR2004/002359 FR2004002359W WO2005026337A3 WO 2005026337 A3 WO2005026337 A3 WO 2005026337A3 FR 2004002359 W FR2004002359 W FR 2004002359W WO 2005026337 A3 WO2005026337 A3 WO 2005026337A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenoviral vector
peptide
cells deficient
infecting cells
car receptor
Prior art date
Application number
PCT/FR2004/002359
Other languages
English (en)
Other versions
WO2005026337A2 (fr
Inventor
Karim Benihoud
Michel Perricaudet
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud
Karim Benihoud
Michel Perricaudet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud, Karim Benihoud, Michel Perricaudet filed Critical Roussy Inst Gustave
Publication of WO2005026337A2 publication Critical patent/WO2005026337A2/fr
Publication of WO2005026337A3 publication Critical patent/WO2005026337A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention a pour objet un vecteur adénoviral qui présente un tropisme pour les cellules CAR- et qui est destiné au transfert de gène ; ce vecteur adénoviral comporte dans au moins une région à faible contrainte structurale d'une protéine de capside, un peptide hétérologue comportant le motif -(W/R)X1X2D-, ledit peptide étant de préférence capable de se lier au TGFβR, et étant de préférence un peptide immunosuppresseur de rétrovirus tel que par exemple le peptide CKS-17. L'invention porte également sur l'utilisation de ce vecteur adénoviral pour le traitement des cancers, de maladies musculaires, ou de la mucoviscidose.
PCT/FR2004/002359 2003-09-18 2004-09-17 Vecteur adenoviral pour l’infection de cellules deficientes en recepteur car WO2005026337A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0310958A FR2860004A1 (fr) 2003-09-18 2003-09-18 Nouveau vecteur adenoviral pour l'infection de cellules deficientes ou depourvues en recepteurs car
FR0310958 2003-09-18

Publications (2)

Publication Number Publication Date
WO2005026337A2 WO2005026337A2 (fr) 2005-03-24
WO2005026337A3 true WO2005026337A3 (fr) 2005-07-28

Family

ID=34224326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/002359 WO2005026337A2 (fr) 2003-09-18 2004-09-17 Vecteur adenoviral pour l’infection de cellules deficientes en recepteur car

Country Status (2)

Country Link
FR (1) FR2860004A1 (fr)
WO (1) WO2005026337A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530672T1 (de) 2001-06-22 2011-11-15 Univ Pennsylvania Rekombinante adenoviren mit affen-adenovirus proteinen und verwendung davon.
WO2008010864A2 (fr) * 2006-04-28 2008-01-24 The Trustees Of The University Of Pennsylvania Protéine hexon d'adénovirus modifiée et ses utilisations
US20090280089A1 (en) * 2006-06-19 2009-11-12 Institut Gustave Roussy Inhibition of the liver tropism of adenoviral vectors
WO2009046860A2 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033818A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
CN102016011B (zh) 2008-03-04 2013-12-11 宾夕法尼亚大学托管会 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用
CN105473723A (zh) 2012-05-18 2016-04-06 宾夕法尼亚大学托管会 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途
WO2014166500A2 (fr) * 2013-04-10 2014-10-16 Skau Aps Peptides ayant des domaines immunosuppresseurs pour la transfection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067576A1 (fr) * 1999-05-12 2000-11-16 The Uab Research Foundation Adenovirus a pouvoir infectant renforce et a replication conditionnelle, et applications de celui-ci
EP1067188A1 (fr) * 1999-07-08 2001-01-10 Introgene B.V. Infection avec les adenovirus chimères des cellules qui sont negative pour le recepteur du serotype 5 d'adenovirus coxsackie adenovirus (CAR)
WO2001092549A2 (fr) * 2000-05-31 2001-12-06 Genvec, Inc. Methode et composition destinees au ciblage d'un vecteur adenoviral
WO2002083902A2 (fr) * 2001-01-09 2002-10-24 University Of Iowa Research Foundation Adenovirus de serotype 30 (ad30)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067576A1 (fr) * 1999-05-12 2000-11-16 The Uab Research Foundation Adenovirus a pouvoir infectant renforce et a replication conditionnelle, et applications de celui-ci
EP1067188A1 (fr) * 1999-07-08 2001-01-10 Introgene B.V. Infection avec les adenovirus chimères des cellules qui sont negative pour le recepteur du serotype 5 d'adenovirus coxsackie adenovirus (CAR)
WO2001092549A2 (fr) * 2000-05-31 2001-12-06 Genvec, Inc. Methode et composition destinees au ciblage d'un vecteur adenoviral
WO2002083902A2 (fr) * 2001-01-09 2002-10-24 University Of Iowa Research Foundation Adenovirus de serotype 30 (ad30)

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BARNETT, B.G. , CREWS, C.J. , DOUGLAS, J.T., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1575, 2002, pages 1 - 14, XP002324028 *
BENIHOUD K ET AL: "ADENOVIRUS VECTORS FOR GENE DELIVERY", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 10, 1999, pages 440 - 447, XP000827843, ISSN: 0958-1669 *
HUANG SHUAN SHIAN; HUANG JUNG SAN: "A pentacosapeptide (CKS-25) homologous to retroviral envelope proteins possesses a transforming growth factor-beta activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 9, 27 February 1998 (1998-02-27), pages 4815 - 4818, XP002282878 *
KIM M ET AL: "The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, no. 14, September 2002 (2002-09-01), pages 1917 - 1926, XP004377460, ISSN: 0959-8049 *
KRASNYKH V ET AL: "Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 3, March 1998 (1998-03-01), pages 1844 - 1852, XP002126061, ISSN: 0022-538X *
VIGNE E, DEDIEU JF, BRIE A, GILLARDEAUX A, BRIOT D, BENIHOUD K, LATTA-MAHIEU M, SAULNIER P, PERRICAUDET M, YEH P: "Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation.", GENE THERAPY, vol. 10, no. 2, January 2003 (2003-01-01), pages 153 - 162, XP002282879 *
WICKHAM T J ET AL: "Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 11, 1 November 1997 (1997-11-01), pages 8221 - 8229, XP002078898, ISSN: 0022-538X *
WICKHAM T J ET AL: "TARGETING OF ADENOVIRUS PENTON BASE TO NEW RECEPTORS THROUGH REPLACEMENT OF ITS RGD MOTIF WITH OTHER RECEPTOR-SPECIFIC PEPTIDE MOTIFS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 2, no. 10, 1 December 1995 (1995-12-01), pages 750 - 756, XP000565559, ISSN: 0969-7128 *
WICKHAM T J: "TARGETING ADENOVIRUS", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 2, January 2000 (2000-01-01), pages 110 - 114, XP001055892, ISSN: 0969-7128 *
WICKHAM TJ: "Ligand-directed targeting of genes to the site of disease.", NAT MED., vol. 9, no. 1, January 2003 (2003-01-01), pages 135 - 139, XP002282877 *

Also Published As

Publication number Publication date
FR2860004A1 (fr) 2005-03-25
WO2005026337A2 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
WO2002053703A3 (fr) Vecteurs aav2 et procedes
WO2005117977A8 (fr) Imagerie a specificite tissulaire et agents therapeutiques ciblant des proteines exprimees sur la surface des cellules endotheliales
WO2006119432A3 (fr) Isolation, clonage, et caracterisation de nouveaux serotypes de virus adeno-associes (avv)
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
WO2007049265A3 (fr) Therapie antimineralocorticoidique contre une infection
WO2004027019A3 (fr) Systemes d'expression raav ameliores destines a une modification genetique de proteines de capside specifiques
WO2008106646A3 (fr) Procédés et formulations pour une thérapie génique topique
WO2002002783A3 (fr) Vecteurs d'expression
WO2007002373A3 (fr) Utilisation de l'herpes simplex virus type 2 mutant dans le traitement du cancer
WO2004011611A3 (fr) Anticorps anti-taci et utilisations de ceux-ci
WO2003068923A3 (fr) Signal d'incorporation de vecteurs de virus de la grippe
WO2004113494A3 (fr) Procedes de production de preparations de virions aav recombinants sensiblement exemptes de capsides vides
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
WO2002029086A3 (fr) Sequences d'acide nucleique differentiellement exprimees dans un tissu cancereux
WO2001047959A3 (fr) Molecules d'acides nucleiques isoles codant pour des antigenes associes au cancers, ces antigenes et leur utilisation
WO2006062402A3 (fr) Hsp et arythmie supraventriculaire
WO2005026337A3 (fr) Vecteur adenoviral pour l’infection de cellules deficientes en recepteur car
WO2005120166A3 (fr) Anticorps pour apoptose selective de cellules
WO2005016132A3 (fr) Diagnostic pour le virus du sras
EP1575992A4 (fr) Proteines chimeres a domaine de transduction proteique/domaine desaminase, composes associes et utilisations correspondantes
WO2002036771A3 (fr) Imagerie, diagnostic et traitement de maladie
WO2007051063A3 (fr) Lignees cellulaires exprimant les gpcr et anticorps associes
WO2005115459A3 (fr) Activite antivirale d'un anticorps monoclonal anti-thymidine kinase
WO2001012660A3 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase